Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus

2004 ◽  
Vol 73 (2) ◽  
pp. 244-249 ◽  
Author(s):  
Le H. Song ◽  
Vu Q. Binh ◽  
Dinh N. Duy ◽  
Thomas C. Bock ◽  
Peter G. Kremsner ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Fas Ligand ◽  
Serum Concentrations ◽  
Soluble Fas ◽  
B Virus ◽  
Soluble Fas Ligand

scholarly journals Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-κB

2001 ◽  
Vol 82 (1) ◽  
pp. 171-182 ◽  
Author(s):  
Jingbo Pan ◽  
Ling-Xun Duan ◽  
Bill S. Sun ◽  
Mark A. Feitelson
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepg2 Cells ◽  
Fas Ligand ◽  
Liver Cells ◽  
Dominant Negative ◽  
Receptor System ◽  
Growth And Survival ◽  
B Virus ◽  
Dominant Negative Inhibitor

The hepatitis B virus-encoded X antigen (HBxAg) may contribute to the development of liver cancer, in part, by stimulating the growth and survival of infected cells in the face of ongoing immune responses. Given that the Fas ligand/receptor system contributes to the pathogenesis of chronic hepatitis B, experiments were designed to test the hypothesis that HBxAg mediates resistance of liver cells to anti-Fas killing. Accordingly, when HBxAg was introduced into HepG2 cells, it rendered these cells partially resistant to killing by anti-Fas. In HepG2 cells replicating virus, protection against anti-Fas killing was also observed, but to a lesser extent. Survival correlated with the activation of nuclear factor kappa B (NF-κB) by HBxAg. Sensitivity to anti-Fas was observed in control cells, and was re-established in HepG2X cells stably transfected with the dominant negative inhibitor of NF-κB, IκBα. HBxAg activation of NF-κB was also associated with decreased levels of endogenous IκBα mRNA. Hence, HBxAg stimulation of NF-κB promotes the survival of liver cells against Fas killing. This may contribute to the persistence of infected hepatocytes during chronic infection.

scholarly journals Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

2010 ◽  
Vol 54 (8) ◽  
pp. 3205-3211 ◽  
Author(s):  
Fukiko Mitsui ◽  
Masataka Tsuge ◽  
Takashi Kimura ◽  
Shosuke Kitamura ◽  
Hiromi Abe ◽  
...  
Keyword(s):  
Renal Function ◽  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Hbv Dna ◽  
Response To Therapy ◽  
Serum Concentrations ◽  
Clearance Rates ◽  
B Virus

ABSTRACT Lamivudine (LMV)-adefovir pivoxil (ADV) combination therapy suppresses the replication of LMV-resistant hepatitis B virus (HBV), although its efficacy in suppressing HBV varies among patients. This study analyzed the clinical, virological, and pharmaceutical factors that influence the effect of the combination therapy. Patients negative for hepatitis B virus e antigen (HBeAg) and with low HBV DNA titers immediately prior to the combination therapy effectively cleared serum HBV DNA (P = 0.0348 and P = 0.0310, respectively). The maximum concentration of ADV in serum (ADV C max) was higher in patients who showed HBV DNA clearance (P = 0.0392), and the cumulative clearance rates of HBV DNA were significantly higher in patients with ADV C max equal to or greater than 24 ng/ml (P = 0.0284). HBeAg negativity and lower HBV DNA at the start of the combination therapy and higher ADV C max were found to be independent factors for serum HBV DNA clearance. Serum creatinine increased significantly during the combination therapy, and the ADV C max was higher in patients with low creatinine clearance rates. In conclusion, higher serum concentrations of ADV are associated with a good response to therapy based on clearance of HBV DNA in serum. However, care should be taken to prevent worsening of renal function due to high ADV serum concentrations.

Serum concentrations of soluble Fas antigen and soluble Fas ligand in mother and newborn

2000 ◽  
Vol 263 (3) ◽  
pp. 108-110 ◽  
Author(s):  
H. Iwama ◽  
H. Akutsu ◽  
S. Kuretake ◽  
J. Tohma ◽  
N. Nakamura
Keyword(s):  
Fas Ligand ◽  
Serum Concentrations ◽  
Fas Antigen ◽  
Soluble Fas ◽  
Soluble Fas Antigen ◽  
Soluble Fas Ligand

scholarly journals Infection with Hepatitis B Virus May Increase the Serum Concentrations of Osteopontin

Intervirology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Hua-Bing Liu ◽  
Qin-Yan Chen ◽  
Xue-Yan Wang ◽  
Lu-Juan Zhang ◽  
Li-Ping Hu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Tumor Development ◽  
Healthy Control Group ◽  
Control Group ◽  
Serum Concentrations ◽  
P Values ◽  
Hbsag Carriers ◽  
B Virus ◽  
Healthy Control

Background: Serum osteopontin (OPN) concentrations were found to be significantly increased in patients infected with hepatitis B virus (HBV) and patients with hepatocellular carcinoma (HCC). Objective: The aim of this study was to determine the association among HCC, OPN, and HBV. Methods: Two hundred and forty-one subjects were recruited and divided into 6 groups: healthy controls, asymptomatic HBsAg carriers, HBsAg (−) patients with other tumors, HBsAg (+) chronic liver disease patients, HBsAg (+) patients with HCC, and HBsAg (−) patients with HCC or liver cirrhosis (LC). Serum concentrations of OPN and HBsAg were measured and analyzed. Results: OPN concentrations in the HBsAg (+) HCC group were significantly higher than the healthy control group and the HBsAg (−) patients with other cancers (both p = 0.0001). The OPN concentrations of the HBsAg (−) patients with HCC or LC also did not differ significantly from those of the healthy control group (p = 0.075). There is a correlation between the titer of HBsAg and concentrations of OPN in all 3 HBsAg (+) groups (all p values <0.05). Conclusions: Infection with HBV may increase the serum concentrations of OPN. The association of OPN and HCC may be not attributable to tumor development per se but, rather, to HBV infection.

Soluble Fas ligand and neopterin in patients with systemic and cutaneous discoid lupus erythematosus

Pteridines ◽  
2000 ◽  
Vol 11 (3) ◽  
pp. 85-89
Author(s):  
Barbara Wirleitner ◽  
Elisabeth Kowald ◽  
Bernhard Widner ◽  
Ulrike Ortner ◽  
Gabriele Baier-Bitterlich ◽  
...  
Keyword(s):  
Immune System ◽  
Lupus Erythematosus ◽  
Fas Ligand ◽  
Discoid Lupus Erythematosus ◽  
Serum Concentrations ◽  
Systemic Lupus ◽  
Serum Samples ◽  
Soluble Fas ◽  
Soluble Fas Ligand ◽  
The Status

SummaryEvidence accumulates suggesting that the pathogenesis in systemic lupus erythematosus (SLE) is associated with modulations in the Fas/FasL system. Serum concentrations of soluble Fas ligand (sFasL) were found to be elevated in patients with SLE. In this study we wanted to determine the levels of sFasL and the status of immune activation - monitored by neopterin secretion - in patients with SLE and cutaneous discoid lupus erythematosus (CDLE). Sixty-five serum samples were assayed. We found elevated concentrations of sFasL in patients with SLE and CDLE. The levels of sFasL in COLE patients were significant lower compared to SLE patients. Neopterin concentrations in serum were found to be slightly increased in patients with CDLE. Compared to patients with SLE, activation of the immune system was significant lower in COLE. Taken together, we found d evated levels of sFasL in patients with SLE as well as CDLE, connected with ar activation of the immune system and thereby increased concentration of neopterin in serum.

Sign in / Sign up

Export Citation Format

Share Document